Fineline Cube

Follow:
14435 Articles
Zhimeng Biopharma's CB03-154 Receives CDE Approval for ALS Phase II/III Clinical Study
CompanyDrug

Zhimeng Biopharma’s CB03-154 Receives CDE Approval for ALS Phase II/III Clinical Study

NHSA Finalizes 2025 Drug Catalog Adjustment Plan with Minimal Changes from Draft
Policy / Regulatory

NHSA Finalizes 2025 Drug Catalog Adjustment Plan with Minimal Changes from Draft

MSD's Once-Daily HIV-1 Therapy Doravirine/Islatravir NDA Accepted by FDA for Review
CompanyDrug

MSD’s Once-Daily HIV-1 Therapy Doravirine/Islatravir NDA Accepted by FDA for Review

Zelgen's ZG006 Receives Breakthrough Therapy Designation for Advanced Small Cell Lung Cancer
CompanyDrug

Zelgen’s ZG006 Receives Breakthrough Therapy Designation for Advanced Small Cell Lung Cancer

Cosunter's GST-HG131 Granted Breakthrough Therapy Designation for HBV Treatment in China
CompanyDrug

Cosunter’s GST-HG131 Granted Breakthrough Therapy Designation for HBV Treatment in China

Ascentage Pharma's Lisaftoclax Receives NMPA Approval for CLL/SLL Treatment
CompanyDrug

Ascentage Pharma’s Lisaftoclax Receives NMPA Approval for CLL/SLL Treatment

Allist's Furmonertinib Granted Priority Review for EGFR Exon 20 NSCLC in China
CompanyDrug

Allist’s Furmonertinib Granted Priority Review for EGFR Exon 20 NSCLC in China

HKYM Biopharma's KM1 Receives NMPA Green-Light for Phase Ib/II Study in Advanced Solid Tumors
CompanyDrug

HKYM Biopharma’s KM1 Receives NMPA Green-Light for Phase Ib/II Study in Advanced Solid Tumors

United Laboratories Receives FDA Approval for Clinical Study of UBT37034 in Overweight/Obesity Treatment
CompanyDrug

United Laboratories Receives FDA Approval for Clinical Study of UBT37034 in Overweight/Obesity Treatment

CStone Pharmaceuticals Receives NMPA Approval for Local Production of Gavreto in China
CompanyDrug

CStone Pharmaceuticals Receives NMPA Approval for Local Production of Gavreto in China

Biocytogen and BeOne Medicines Deepen Partnership with Global Antibody Licensing Agreement
CompanyDeals

Biocytogen and BeOne Medicines Deepen Partnership with Global Antibody Licensing Agreement

Eli Lilly's Kisunla (Donanemab) Receives FDA Label Update with New Dosing Schedule for Alzheimer's Treatment
CompanyDrug

Eli Lilly’s Kisunla (Donanemab) Receives FDA Label Update with New Dosing Schedule for Alzheimer’s Treatment